Protocols: Merck punts ALK allergy meds; Gene editing gets mixed reviews by a wary public
Just a few months ago, Merck capped a 9-year alliance with Denmark’s ALK on new allergy medicines by noting that the FDA had accepted its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
